Skip to main content
Fig. 3 | Arthritis Research & Therapy

Fig. 3

From: TRPA1 as a potential factor and drug target in scleroderma: dermal fibrosis and alternative macrophage activation are attenuated in TRPA1-deficient mice in bleomycin-induced experimental model of scleroderma

Fig. 3

Pro-fibrotic factor expression in the skin of bleomycin-treated TRPA1-deficient mice was inhibited. TGF-β1 (A), fibronectin-1 (B), CTGF (C), YKL-40 (D), IL-6 (E), MCP-1 (F), and COX-2 (G) expression in the skin from WT and TRPA1-deficient (TRPA1−/−) mice treated with bleomycin were assessed by RT-PCR and normalized against GAPDH mRNA. WT control was given the value of 1 and the other values are set in the proportion to that value. Data are expressed as mean + SEM; n =  6. *p < 0.05, **p < 0.01 between bleomycin treated WT and TRPA1-deficient mice; #p < 0.05, ##p < 0.01, ###p < 0.001, p = 0.0518, p = 0.0501 between control and bleomycin treated mice within the same genotype

Back to article page

Arthritis Research & Therapy

ISSN: 1478-6362

Contact us